We’re building a venture with a new way to treat hypoxic-ischemic encephalopathy in newborn babies and limit the damage of their brain.
Are you the driven entrepreneur who’ll lead this venture as the CEO?
Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by a shortage of blood and oxygen to the brain. It has devastating long-term consequences for the babies including cerebral palsy, cognitive deficits and epilepsy. A research team at the Maastricht University has come up with a new approach to treat HIE and reduce permanent brain damage in these neonates. By using the protein AnnexinA1, they can restore the disrupted blood-brain barrier and limit this devastating damage.
The position of CEO
The CEO will be responsible for developing and executing the overall drug development and business strategy, actively supported by NLC The European Healthtech Venture Builder. This also includes partnering with the researchers and other strategic partners.
- Develop comprehensive drug development, business and funding plans.
- Coordinate and guide early drug development from preclinical animal studies into an actual clinical solution incl. overseeing (pre)clinical studies and finding and managing relevant partners.
- Apply for Orphan Drug Designation and steer claim- and product development accordingly.
- Fundraising: seek and secure non-dilutive and dilutive funding supported by NLC’s Venture Finance Team.
- Anticipate market introduction: steer product development in accordance to market needs
CEO competencies and track record
We seek a highly motivated leader that masters these competencies:
- Entrepreneurial drive.
- Networking and influencing at all levels of seniority.
- Excellent communication skills, particularly strong presentation and negotiation skills.
Your track record includes:
- Early drug development gained in a commercial setting, including in-vivo preclinical experience, preferable in the field of proteins or small molecules but this is not a must-have.
- Ability to translate an academic project to a commercial environment and bring it further in collaboration with the researchers and relevant partners.
- Fundraising experience in non-dilutive funding and dilutive funding.
- Familiarity with regulatory affairs and the steps to be taken to obtain (pre)clinical trial authorizations, preferable in the area of orphan drugs but this is not a must-have.
We offer the unique opportunity to an entrepreneur or executive with entrepreneurial ambition to come on board as a partner (essentially co-founder) in a highly promising venture. The participation package includes:
- Equity-based remuneration.
- Cash compensation tied to successful funding of the company.
- The opportunity to Co-fund at a favorable valuation.
- Access to the expertise and network of the entire NLC ecosystem including the use of NLC Venture Services.
- Sparring and support from your Venture Partner and the dozens of CEO’s leading our other (50+) ventures.
- Last but not least: You will play a key role in developing and introducing a new therapy to neonates experiencing HIE with currently no effective therapy options available to them.
For more information please contact Eva Demandt (Venture Teaming) via email@example.com